Gland Pharma reported a strong performance for the quarter ended March 2026, with sharp growth in revenue and profitability on a year-on-year basis.
The pharmaceutical company posted consolidated revenue from operations of ₹1,742.79 crore in Q4 FY26, compared to ₹1,424.91 crore in the corresponding quarter last year, registering a growth of 22.3% YoY.
Total income for the quarter stood at ₹1,854.26 crore against ₹1,468.94 crore in Q4 FY25, reflecting an increase of 26.2%.
Gland Pharma’s profit before tax surged to ₹505.80 crore in the March 2026 quarter, up 75.5% from ₹288.33 crore reported a year ago.
The company reported a consolidated net profit of ₹366.68 crore for Q4 FY26, compared to ₹186.54 crore in Q4 FY25, marking a sharp jump of 96.6% YoY.
Employee benefit expenses increased to ₹411.57 crore from ₹373.37 crore, while depreciation and amortisation expenses rose to ₹108.66 crore against ₹95.76 crore in the year-ago period.
Other expenses also climbed to ₹173.85 crore compared to ₹163.47 crore in Q4 FY25.
For the full financial year ended March 2026, Gland Pharma reported revenue from operations of ₹6,430.65 crore, up 14.5% from ₹5,616.50 crore in FY25.
Annual net profit came in at ₹1,027.32 crore, registering a growth of 47.1% over ₹698.53 crore reported in the previous financial year.
The company’s total expenses for FY26 rose to ₹5,258.05 crore from ₹4,767.45 crore in FY25, mainly due to higher employee costs and operational spending.